Bristol-myers Squibb Compnay

Other

Kenneth M Tramposch

Fred Christopher Zusi

Xina Nair

Anne Marinier

R Thomas Swann

Daniel Smith

Anna M Ericsson

Makonen Belema

Alain Martel

John E Starrett, Jr

Anita H Lewin

F Christopher Zusi

F Ivy Carroll

Peter R Reczek

Ronald J Shannon

Suresh Marathe

Karyn A Monte

Stephen A Steiner

William Somerville

Disclosed is the (R)-enantiomer of the formula

Active enantiomer of RAR&ggr;-specific agonist

Retinoid antagonists and uses thereof

The present invention relates to methods of preventing, or reducing the severity of, an ischemic injury originating in an animal's dermal tissue by applying to the animal a composition comprising a compound of formula I*: ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in which

Use of substituted (5,6) dihydronaphthalenyl compounds having

Certain novel substituted (5,6)-dihydroanthracenyl compounds of the general formula ##STR1## wherein A, n, p, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification exhibit retinoid-like properties and are particularly useful in the prevention of post-surgical adhesions.

Retinoid-like compounds

Retinoid-like activity is exhibited by compounds of the formula ##STR1## wherein X is F, Cl, OH or CH.sub.3, Y is H or F, R.sub.1 -R.sub.6 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, n is an integer of 1 to 4 and R.sub.7 is hydrogen or a carboxyl-protecting group, and pharmaceutically acceptable salts thereof. The compounds of the formula I selectively interact with the retinoic acid subtype RAR.gamma. and have been found to lack the liver toxicity associated with systemic administration of non-relative retinoids.

RAR.gamma.-specific retinobenzoic acid derivatives

Retinoid-like activity is exhibited by compounds of the formula ##STR1## wherein X is F, Cl, OH or CH.sub.3, Y is H or F, R.sub.1 -R.sub.6 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl, n is an integer of 1 to 4 and R.sub.7 is hydrogen or a carboxyl-protecting group, and pharmaceutically acceptable salts thereof. The compounds of formula I selectively interact with the retinoic acid subtype RAR.gamma. and have been found to lack the liver toxicity associated with systemic administration of non-selective retinoids.

Rary-specific retinobenzoic acid derivatives

There is disclosed a synergistic composition and process for skin depigmentation with reduced irritation which does not employ a corticosteroid and which employs a substituted oxybenzene and a retinoid.

Synergistic skin depigmentation composition

New compounds (3-alkyl-5-hydroxy-3,4-dihydrofuran-2-ones) of the following general structure: ##STR1## wherein R is an alkyl group or a phenylalkyl group with the alkyl moiety containing at least 6 carbon atoms, are disclosed as useful in inhibiting phospholipase A.sub.2.

Furanone anti-inflammatory agents

There is disclosed a synergistic composition for skin depigmentation with reduced irritation which does not contain a corticosteroid comprising 4-hydroxyanisole and a retinoid, such as all-trans retinoic acid, 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone or (N-acetyl-4-aminophenyl) retinoate, in a pharmaceutically acceptable topical vehicle.

Compounds of the formula ##STR1## wherein R.sub.1 is CH.dbd.CY--C(CH.sub.3).dbd.CHX wherein X and Y are different and each is of the formula ##STR2## wherein R' and R' independently are H or alkyl of C.sub.1-6 and R.sub.1 includes all possible geometric isomers are demonstrated effective in treating inflammation, both topically and internally. The mechanism appears to be the inhibition of phospholipase A.sub.2 enzymes.

Growing community of inventors

E. Amherst, NY, United States of America

Kenneth M Tramposch